Objective: Smoking tobacco cigarettes after a cancer diagnosis increases risk for several serious adverse outcomes. Thus, patients can significantly benefit from quit- Results: Most participants identified smoking cessation as the reason for initiating (81%) and continuing (60%) e-cigarette use. However, 51% of patients reported current dual use of combustible cigarettes and e-cigarettes, and most patients reported never having discussed their use of e-cigarettes with their oncology provider (72%).
| BACKGROUND
Individuals who continue to smoke combustible cigarettes (hereafter referred to as cigarettes) after receiving a cancer diagnosis are at increased risk for adverse outcomes. The Surgeon General's Report 1 found sufficient evidence for a causal relationship between continued smoking and all-cause mortality, cancer-specific mortality, and increased risk of second primary cancers. Continued smoking is also associated with an increased risk of cancer recurrence, poorer treatment response, and treatment side effects. 2 Thus, quitting smoking is imperative for patients with cancer, yet a recent national study found that 65% of patients with cancer who smoke continue to do so after diagnosis. 3 There are several pharmacotherapies, including nicotine replacement therapies (NRT), that are effective at promoting smoking cessation and are approved by the US Food and Drug Administration.
However, the emergence of electronic cigarettes (ECIGS) has resulted in smokers more frequently reporting using ECIGS than NRT for smoking cessation. 4 Given the rising popularity of ECIGS, it is not surprising that ECIG use is also increasing among patients with cancer; a 2014 study found that nearly 40% of patients with cancer who smoked reported ECIG use. 5 Relatively little is known about the use of ECIGS by patients with cancer. Thus, the American Association reported ever-use of ECIGS, 221 (12%) reported current use of ECIGS, and 123 of these (56%) consented to the study. Data from 121 completed surveys were analyzed (1 withdrew, 1 deemed ineligible after consenting). Only 1.1% of data were missing (see tables for n's).
On average, participants were 55.6 years old (SD = 9.9), and the sample was 56.2% female and 88. 
| ECIG use patterns, intentions, and reasons for use
As seen in Table 1 , most participants (72%) reported using ECIGS daily ≥5 times per day and reported no plans to stop using ECIGS within the next year. Most participants (68%) reported using refillable, tankbased ECIG devices, and tobacco was the most common flavor preference. Exclusive ECIG users were more likely to use ECIGS more times per day than dual users (χ 2 (3) = 9.467, P = .024). Although a third of participants had no intentions of quitting ECIGS, a third had plans to quit within the next 6 months. There was no significant difference between dual users and exclusive ECIG users in plans for quitting ECIGS. The most common source of information about ECIGS was from friends/family (N = 50; 41%), whereas only 2 participants (1.6%) reported receiving information from healthcare providers. As seen in Table 2 , smoking cessation was the most frequently endorsed reason for initiating (81%) and maintaining (60%) ECIG use. Forty-two percent of the sample initiated ECIG use after their cancer diagnosis, and 21% initiated ECIGS because of health concerns related to their cancer diagnosis. 
| ECIGS versus combustible cigarettes

| ECIGS versus NRT
As seen in Table 3 , although NRT was rated as less addictive, less likely to generate cravings, less likely to result in negative social impressions, and more likely to be recommended by their oncology provider, participants viewed ECIGS as less expensive, less irritating, more satisfying, and more convenient. Participants also viewed ECIGS as more useful for smoking cessation, better at relieving cancer-related stress, and less addictive than tobacco cigarettes when compared to NRT.
| Patient-oncology provider communication
As seen in Table 4 , participants felt comfortable discussing ECIGS with their oncology provider and believed it was important to do so. However, the vast majority of participants reported not knowing their provider's stance on ECIGS because it was never discussed. 
| DISCUSSION
Approximately one in 5 patients with cancer who were current or former smokers reported trying ECIGS, somewhat lower than previously reported. 5 Consistent with studies of the general population, 20, 21 many patients reported initiating ECIGS to quit smoking. Furthermore, 42% of participants initiated ECIG use after their cancer diagnosis, and 21% of the sample endorsed "health concerns due to their cancer diagnosis" as a reason for initiating ECIGs. These findings reflect unique motivators of ECIG use within this population that could inform provider communication to patients about the relationship between ECIG use, smoking cessation, and cancer care.
To our knowledge, our study is the first to evaluate beliefs for ECIGS, NRTs, and cigarettes of patients with cancer. Compared to cigarettes, ECIGS were considered to be less addictive, more practical to use, better tasting, less stigmatizing, less likely to cause negative physical feelings, and less likely to be associated with health risks. ECIGS
were also noted to be less expensive-an important consideration as the policy landscape surrounding ECIGS evolves (ie, ECIG taxation).
These findings are consistent with previous studies evaluating such beliefs within the general population of ECIG users. 14, 22 Additionally, patients perceived ECIGS as less detrimental to their cancer treatment effectiveness and less likely to increase the risk of cancer treatmentrelated problems. In contrast, cigarettes were viewed as more effective for managing negative mood and reducing stress. Affect modulation is a robust motivator for initiation and maintenance of smoking. 23 Given elevated stress and mood changes that occur after a cancer diagnosis, this finding may help explain why many patients with cancer cannot quit smoking despite the motivation to do so, as well as why they choose ECIGS as a cessation aid.
A smoker's decision regarding the type of cessation aid to use may be influenced in part by beliefs about the relative benefits and risks of each product. 24 NRTs were perceived as less addictive, less cravinginducing, and less socially stigmatizing than ECIGS. However, patients also perceived several key advantages of ECIGS over NRT related to cost, physical irritation, and convenience. Effect sizes suggest that the largest perceived advantages of ECIGS were in taste, craving reduction, and relief of negative affect and stress, including cancerrelated stress. Because stress and negative affect are often cited causes of smoking relapse in the general 23 and patient with cancer populations, 25 these latter perceived advantages may be especially helpful for maintaining smoking abstinence. It is notable that participants believed that ECIGS are more useful for smoking cessation than NRT, and given that three-fourths of participants in our sample had used NRT, their beliefs were likely based on dissatisfying prior experiences with NRT.
Patients with cancer often look to their physicians for support and advice, 26 and provider advice can facilitate smoking cessation. 27 Our Cancer. 29 However, British public health organizations have taken a more encouraging stance on ECIGS as a harm reduction innovation Significant difference between ECIG and cigarette/NRT ratings (P < .05).
b Likert scale ranging from 1-strongly disagree to 7-strongly agree. ; consequently, the majority of British practitioners ask patients about ECIG use. 31 Given the more conservative approach in the USA, it is possible that oncology providers fear that discussing ECIGS may implicitly encourage use of ECIGS.
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Because smoking can cause adverse cancer outcomes, it is critical for oncologists to assist their patients with smoking cessation and to educate patients about the risks and benefits of using ECIGS. Consistent with our participants' perceptions, a recent report from the National Academies of Sciences, Engineering, and Medicine concluded that ECIGS are far less harmful than cigarettes. 33 A recent meta-analysis found that ECIGS may indeed increase smoking cessation 34 and is consistent with national survey findings, 35 yet the National Academies report concluded that there was "insufficient evidence" from randomized controlled trials that e-cigarettes can help people quit smoking. Of note, approximately half of our sample successfully quit smoking using ECIGS.
Those who had successfully quit smoking were more like to vape frequently and to use a tank system, most likely because of more efficient nicotine delivery. Future longitudinal research is needed to further examine use characteristics that predict successful cessation in this population.
| Study limitations
The implications of this cross-sectional study should be considered within the context of its limitations. Our study included patient report of physician communication. Research suggests that providers report higher rates of counseling than patients. 36 We did not assess ECIG beliefs among those who tried but discontinued ECIGS or those who never tried ECIGS. Future research with these groups would provide a more comprehensive perspective on patients' beliefs of ECIGS.
| Clinical implications
Overall, our findings suggest that although ECIGS are not viewed as a completely satisfying alternative to tobacco cigarettes, they are perceived by patients with cancer to be a more appealing option for nicotine replacement than NRT. There is emerging evidence that ECIGS may be an effective smoking cessation aid, 35, 37, 38 perhaps more so than NRT, 39 yet there are insufficient data on their efficacy with patients with cancer. Patients with cancer are, however, increasingly turning to ECIGS, often without their provider's awareness or input.
This study highlights the high prevalence of ECIG use among patients with cancer, reasons and beliefs underlying their ECIG use, and improvements oncologists can make in discussing ECIG use with their patients. Our data show that many patients with cancer initiate ECIG use after diagnosis and do so for the purpose of smoking cessation.
Cancer diagnosis has been described as a "teachable moment" during which patients are highly motivated to quit smoking, and providers can capitalize on this window of opportunity. 40 As research about ECIGS continues to emerge, it is critical for oncology providers to be knowledgeable about ECIGS, to discuss benefits of harm reduction, and to communicate that the long-term health consequences of continued ECIG use are not yet fully known. 
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